• Policy
• The benefit standard for Braftovi & Lorviqua was set
• by Lee, Hye-Kyung Jan 19, 2022 06:06am

• Policy
• Daewoong tx are being developed for skin side effects
• by Lee, Tak-Sun Jan 18, 2022 06:06am

• Policy
• Discord in system hinder coverage of rare disease drugs
• by Lee, Jeong-Hwan Jan 18, 2022 06:06am

• Policy
• The gov will push for a refund on losses from suspension
• by Kim, Jung-Ju Jan 18, 2022 06:05am

• Policy
• A plan to expand patient access to Kymriah should be passed
• by Kim, Jung-Ju Jan 17, 2022 05:51am

• Policy
• The ultra-high-priced new drug Kymriah passed the Committee
• by Lee, Hye-Kyung Jan 14, 2022 05:50am

• Policy
• MOHW·MOTIE accelerates Global COVID-19 Vaccine Hub project
• by Kim, Jung-Ju Jan 14, 2022 05:50am

• Policy
• COVID-19 vaccine by NovaVax is approved in Korea
• by Lee, Tak-Sun Jan 14, 2022 05:50am

• Policy
• The timing of approval for Novavax vaccine is unpredictable
• by Lee, Tak-Sun Jan 13, 2022 02:54pm

• Policy
• NHRC issues ‘expedited listing of Kymriah’ opinion to MOHW
• by Lee, Jeong-Hwan Jan 13, 2022 06:05am